Absence of immune responses with xenogeneic collagen and elastin

Tissue Engineering - Part A

Volumn 19, Issue 13-14, 2013, Pages 1592-1600

  Bayrak, Alexandra ^a   Prüger, Pauline ^a   Stock, Ulrich A ^b   Seifert, Martina ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ENGINEERING; CELL PROLIFERATION; COLLAGEN; ELASTIN; FLOW CYTOMETRY; GLYCOPROTEINS; MAMMALS; PHYSIOLOGY; PURIFICATION; TISSUE;

ADAPTIVE IMMUNITY; BOVINE COLLAGEN; COLLAGEN TYPE I; CYTOKINE SECRETIONS; EXTRACELLULAR MATRIX PROTEIN; HUMAN DENDRITIC CELLS; TISSUE-ENGINEERED SCAFFOLDS; TUMOR NECROSIS FACTORS;

SCAFFOLDS (BIOLOGY);

BOVINAE; SUS;

COLLAGEN; ELASTIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; BOVINAE; CYTOLOGY; DENDRITIC CELL; EXTRACELLULAR MATRIX; HUMAN; IMMUNOLOGY; METABOLISM; MONONUCLEAR CELL; SWINE; ARTICLE; CATTLE;

ANIMALS; CATTLE; COLLAGEN; DENDRITIC CELLS; ELASTIN; EXTRACELLULAR MATRIX; HUMANS; LEUKOCYTES, MONONUCLEAR; SWINE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84878394144     PISSN: 19373341     EISSN: 1937335X     Source Type: Journal    
DOI: 10.1089/ten.tea.2012.0394     Document Type: Article

References (53)

1. Piterina, A.V., Cloonan, A.J., Meaney, C.L., Davis, L.M., Callanan, A., Walsh, M.T., and McGloughlin, T.M. ECMbased materials in cardiovascular applications: inherent healing potential and augmentation of native regenerative processes. Int J Mol Sci 10, 4375, 2009.
2. Akhyari, P., Minol, P., Assmann, A., Barth, M., Kamiya, H., and Lichtenberg, A. [Tissue engineering of heart valves]. Chirurg 82, 311, 2011.
3. Gilbert, T.W., Sellaro, T.L., and Badylak, S.F. Decellularization of tissues and organs. Biomaterials 27, 3675, 2006.
4. Schoen, F.J. Heart valve tissue engineering: quo vadis? Curr Opin Biotechnol 22, 698, 2011.
5. Simon, P., Kasimir, M.T., Seebacher, G., Weigel, G., Ullrich, R., Salzer-Muhar, U., Rieder, E., and Wolner, E. Early failure of the tissue engineered porcine heart valve SYNERGRAFT in pediatric patients. Eur J Cardiothorac Surg 23, 1002, 2003.
6. Courtman, D.W., Errett, B.F., and Wilson, G.J. The role of crosslinking in modification of the immune response elicited against xenogenic vascular acellular matrices. J Biomed Mater Res 55, 576, 2001.
7. Bloch, O., Golde, P., Dohmen, P.M., Posner, S., Konertz, W., and Erdbrugger, W. Immune response in patients receiving a bioprosthetic heart valve: lack of response with decellularized valves. Tissue Eng Part A 17, 2399, 2011.
8. Choi, S.Y., Jeong, H.J., Lim, H.G., Park, S.S., Kim, S.H., and Kim, Y.J. Elimination of alpha-gal xenoreactive epitope: alpha-galactosidase treatment of porcine heart valves. J Heart Valve Dis 21, 387, 2012.
9. Pankajakshan, D., Krishnan, V.K., and Krishnan, L.K. Functional stability of endothelial cells on a novel hybrid scaffold for vascular tissue engineering. Biofabrication 2, 041001, 2010.
10. Piterina, A.V., Callanan, A., Davis, L., Meaney, C., Walsh, M., and McGloughlin, T.M. Extracellular matrices as advanced scaffolds for vascular tissue engineering. Biomed Mater Eng 19, 333, 2009.
11. Schenke-Layland, K., Rofail, F., Heydarkhan, S., Gluck, J.M., Ingle, N.P., Angelis, E., Choi, C.H., MacLellan, W.R., Beygui, R.E., Shemin, R.J., and Heydarkhan-Hagvall, S. The use of three-dimensional nanostructures to instruct cells to produce extracellular matrix for regenerative medicine strategies. Biomaterials 30, 4665, 2009.
12. Heydarkhan-Hagvall, S., Schenke-Layland, K., Dhanasopon, A.P., Rofail, F., Smith, H., Wu, B.M., Shemin, R., Beygui, R.E., and MacLellan, W.R. Three-dimensional electrospun ECM-based hybrid scaffolds for cardiovascular tissue engineering. Biomaterials 29, 2907, 2008.
13. Sell, S.A., Wolfe, P.S., Ericksen, J.J., Simpson, D.G., and Bowlin, G.L. Incorporating platelet-rich plasma into electrospun scaffolds for tissue engineering applications. Tissue Eng Part A 17, 2723, 2011.
14. Del Gaudio, C., Grigioni, M., Bianco, A., and De Angelis, G. Electrospun bioresorbable heart valve scaffold for tissue engineering. Int J Artif Organs 31, 68, 2008.
15. Badylak, S.F., and Gilbert, T.W. Immune response to biologic scaffold materials. Semin Immunol 20, 109, 2008.
16. Kou, P.M., and Babensee, J.E. Validation of a highthroughput methodology to assess the effects of biomaterials on dendritic cell phenotype. Acta Biomater 6, 2621, 2010.
17. Franz, S., Rammelt, S., Scharnweber, D., and Simon, J.C. Immune responses to implants-a review of the implications for the design of immunomodulatory biomaterials. Biomaterials 32, 6692, 2011.
18. Brown, B.N., Valentin, J.E., Stewart-Akers, A.M., McCabe, G.P., and Badylak, S.F. Macrophage phenotype and remodeling outcomes in response to biologic scaffolds with and without a cellular component. Biomaterials 30, 1482, 2009.
19. Bianchi, M.E. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 81, 1, 2007.
20. Shokouhi, B., Coban, C., Hasirci, V., Aydin, E., Dhanasingh, A., Shi, N., Koyama, S., Akira, S., Zenke, M., and Sechi, A.S. The role of multiple toll-like receptor signalling cascades on interactions between biomedical polymers and dendritic cells. Biomaterials 31, 5759, 2010.
21. Babensee, J.E., and Paranjpe, A. Differential levels of dendritic cell maturation on different biomaterials used in combination products. J Biomed Mater Res Part A 74, 503, 2005.
22. Yoshida, M., and Babensee, J.E. Poly(lactic-co-glycolic acid) enhances maturation of human monocyte-derived dendritic cells. J Biomed Mater Res Part A 71, 45, 2004.
23. Rogers, T.H., and Babensee, J.E. The role of integrins in the recognition and response of dendritic cells to biomaterials. Biomaterials 32, 1270, 2011.
24. Norton, L.W., Park, J., and Babensee, J.E. Biomaterial adjuvant effect is attenuated by anti-inflammatory drug delivery or material selection. J Control Release 146, 341, 2010.
25. Sprague, L., Muccioli, M., Pate, M., Meles, E., McGinty, J., Nandigam, H., Venkatesh, A.K., Gu, M.Y., Mansfield, K., Rutowski, A., Omosebi, O., Courreges, M.C., and Benencia, F. The interplay between surfaces and soluble factors define the immunologic and angiogenic properties of myeloid dendritic cells. BMC Immunol 12, 35, 2011.
26. Kohl, K., Schnautz, S., Pesch, M., Klein, E., Aumailley, M., Bieber, T., and Koch, S. Subpopulations of human dendritic cells display a distinct phenotype and bind differentially to proteins of the extracellular matrix. Eur J Cell Biol 86, 719, 2007.
27. Garcia-Nieto, S., Johal, R.K., Shakesheff, K.M., Emara, M., Royer, P.J., Chau, D.Y., Shakib, F., and Ghaemmaghami, A.M. Laminin and fibronectin treatment leads to generation of dendritic cells with superior endocytic capacity. PLoS One 5, e10123, 2010.
28. DiLillo, D.J., Horikawa, M., and Tedder, T.F. B-lymphocyte effector functions in health and disease. Immunol Res 49, 281, 2011.
29. Pierce, S.K., and Liu, W. The tipping points in the initiation of B cell signalling: how small changes make big differences. Nat Rev Immunol 10, 767, 2010.
30. Morva, A., Lemoine, S., Achour, A., Pers, J.O., Youinou, P., and Jamin, C. Maturation and function of human dendritic cells are regulated by B lymphocytes. Blood 119, 106, 2012.
31. Ferreira, K.S., Almeida, S.R., Ribeiro, C.H., Mariano, M., and Lopes, J.D. Modulation of proliferation, differentiation and cytokine secretion of murine B-1b cells by proteins of the extracellular matrix. Immunol Lett 86, 15, 2003.
32. Borges, O., Borchard, G., de Sousa, A., Junginger, H.E., and Cordeiro-da-Silva, A. Induction of lymphocytes activated marker CD69 following exposure to chitosan and alginate biopolymers. Int J Pharm 337, 254, 2007.
33. Smith, M.J., White, K.L., Jr., Smith, D.C., and Bowlin, G.L. In vitro evaluations of innate and acquired immune responses to electrospun polydioxanone-elastin blends. Biomaterials 30, 149, 2009.
34. Lynn, A.K., Yannas, I.V., and Bonfield, W. Antigenicity and immunogenicity of collagen. J Biomed Mater Res B Appl Biomater 71, 343, 2004.
35. Bayrak, A., Tyralla, M., Ladhoff, J., Schleicher, M., Stock, U.A., Volk, H.D., and Seifert, M. Human immune responses to porcine xenogeneic matrices and their extracellular matrix constituents in vitro. Biomaterials 31, 3793, 2010.
36. Stoddard, M.B., Pinto, V., Keiser, P.B., and Zollinger, W. Evaluation of a whole-blood cytokine release assay for use in measuring endotoxin activity of group B Neisseria meningitidis vaccines made from lipid A acylation mutants. Clin Vaccine Immunol 17, 98, 2010.
37. Jones, K.S. Assays on the influence of biomaterials on allogeneic rejection in tissue engineering. Tissue Eng Part B Rev 14, 407, 2008.
38. Hinderer, S., Schesny, M., Bayrak, A., Ibold, B., Hampel, M., Walles, T., Stock, U.A., Seifert, M., and Schenke-Layland, K. Engineering of fibrillar decorin matrices for a tissueengineered trachea. Biomaterials 33, 5259, 2012.
39. Steinman, R.M., Hawiger, D., and Nussenzweig, M.C. Tolerogenic dendritic cells. Annu Rev Immunol 21, 685, 2003.
40. Xie, Y., Zhou, N.J., Gong, Y.F., Zhou, X.J., Chen, J., Hu, S.J., Lu, N.H., and Hou, X.H. Th immune response induced by H pylori vaccine with chitosan as adjuvant and its relation to immune protection. World J Gastroenterol 13, 1547, 2007.
41. van der Lubben, I.M., Verhoef, J.C., Borchard, G., and Junginger, H.E. Chitosan and its derivatives in mucosal drug and vaccine delivery. Eur J Pharm Sci 14, 201, 2001.
42. Brand, U., Bellinghausen, I., Enk, A.H., Jonuleit, H., Becker, D., Knop, J., and Saloga, J. Influence of extracellular matrix proteins on the development of cultured human dendritic cells. Eur J Immunol 28, 1673, 1998.
43. Zhou, L.J., and Tedder, T.F. Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily. J Immunol 154, 3821, 1995.
44. Acharya, A.P., Dolgova, N.V., Clare-Salzler, M.J., and Keselowsky, B.G. Adhesive substrate-modulation of adaptive immune responses. Biomaterials 29, 4736, 2008.
45. Caraux, A., Klein, B., Paiva, B., Bret, C., Schmitz, A., Fuhler, G.M., Bos, N.A., Johnsen, H.E., Orfao, A., and Perez-Andres, M. Circulating human B and plasma cells. Age-associated changes in counts and detailed characterization of circulating normal CD138-and CD138 + plasma cells. Haematologica 95, 1016, 2010.
46. Bernasconi, N.L., Traggiai, E., and Lanzavecchia, A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 298, 2199, 2002.
47. Bernasconi, N.L., Onai, N., and Lanzavecchia, A. A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. Blood 101, 4500, 2003.
48. Booth, J.S., Arsenault, R., Napper, S., Griebel, P.J., Potter, A.A., Babiuk, L.A., and Mutwiri, G.K. TLR9 signaling failure renders Peyer's patch regulatory B cells unresponsive to stimulation with CpG oligodeoxynucleotides. J Innate Immun 2, 483, 2010.
49. Roberts, T.L., Turner, M.L., Dunn, J.A., Lenert, P., Ross, I.L., Sweet, M.J., and Stacey, K.J. B cells do not take up bacterial DNA: an essential role for antigen in exposure of DNA to toll-like receptor-9. Immunol Cell Biol 89, 517, 2011.
50. Vollmer, J., and Bellert, H. In vitro effects of adjuvants on B cells. Methods Mol Biol 626, 131, 2010.
51. Abdi, J., Engels, F., Garssen, J., and Redegeld, F.A. Toll-like receptor-9 triggering modulates expression of alpha-4 integrin on human B lymphocytes and their adhesion to extracellular matrix proteins. Exp Hematol 39, 927, 2011.
52. Wilhite, T., Ezzelarab, C., Hara, H., Long, C., Ayares, D., Cooper, D.K.C., and Ezzelarab, M. The effect of Gal expression on pig cells on the human T-cell xenoresponse. Xenotransplantation 19, 56, 2012.
53. Yoshida, R., Vavken, P., and Murray, M.M. Decellularization of bovine anterior cruciate ligament tissues minimizes immunogenic reactions to alpha-gal epitopes by human peripheral blood mononuclear cells. Knee 19, 672, 2012.